Key result
Direct fetal therapy with intramuscular digoxin and intraperitoneal flecainide resulted in a favourable outcome in a fetus with refractory SVT and hydrops.
Why the study?
The role of direct fetal therapy requires highlighting in cases of refractory supraventricular tachyarrhythmia presenting with non-immune hydrops.
Does direct fetal therapy improve outcomes in refractory fetal SVT with hydrops?
Comparison
Direct fetal intramuscular digoxin and intraperitoneal flecainide after initial oral digoxin and flecainide
Design
Case report
Authors
Loading...
May support direct fetal therapy in refractory fetal SVT with hydrops; leaves open need for prospective trials.
Case Report (n=1)
Does direct fetal therapy improve outcomes in refractory fetal SVT with hydrops?
Direct fetal therapy with intramuscular digoxin and intraperitoneal flecainide may be an effective strategy for refractory fetal SVT with hydrops when transplacental therapy fails.
Agarwal et al. (2023) conducted a case report in Fetal hydrops and supraventricular tachyarrhythmia (SVT) (n=1). Direct fetal therapy (intramuscular digoxin and intraperitoneal flecainide) was evaluated on Fetal outcome. Direct fetal therapy with intramuscular digoxin and intraperitoneal flecainide resulted in a favourable outcome in a fetus with refractory SVT and hydrops.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: